THIS MEETING HAS BEEN ACCREDITED WITH 5 CPD POINTS
Welcome to the UK Clinical Vaccine Network Conference 2019, a single day conference focusing on the future direction and challenges within the vaccine arena, and set to be the go-to annual conference for all those interested in vaccine development and use. The aim of the conference is to showcase the work of the UK clinical vaccine community and will be open to anyone who wants to learn more about vaccines. Topics covered will range from correlates of protection, adjuvants and novel delivery and AMR, through to global vaccines and vaccine acceptance. As part of the event we will also be holding a masterclass session for trainees and will have a plenary speaker talking about careers in vaccinology………..so something for everyone! The inaugural Clinical Vaccine Network Conference will this year be held at the beautiful Wolfson College in Oxford, a fantastic location within the UK, currently a hive of vaccine research. A hot topic within the vaccine community is that vaccines may help slow down the development of antimicrobial resistance and offer solutions for those infections with limited antibiotic options. The UK Review on AMR recognised vaccines as a priority area and has highlighted the need to increase uptake of current vaccines and to develop new vaccines. Last month alone, the Department of Health and Social Care awarded £1 million to accelerate development of bacterial vaccines to tackle AMR. The conference has been established to showcase UK vaccine research such as this and will generate discussion on future research directions. So please register and join us in what promises to be the first of many exciting vaccine conferences. We look forward to welcoming you to the UK Clinical Vaccine Network Conference 2019!
Dr Alexander Douglas leads a vaccine development group in the Jenner Institute, with interests in rabies and malaria. He previously worked clinically in the NHS as an infectious disease / general medicine SpR. He is now in full-time research, supported by a Wellcome Trust Career Development Fellowship, and is undertaking Pharmaceutical Medicine Specialty Training. His current work on rabies aims to develop a low-cost single-dose vaccine.